Scope and Claims Analysis for US Patent 9,238,657: How Broad Are the Compound, Salt/Solvate, Formulation, and Method Claims?
US Drug Patent 9,238,657 claims a family of quaternary-ammonium-containing antimicrobial compounds (and specific structural subsets), plus downstream claim types: esters, protected amines, pharmaceutically acceptable salts/solvates, pharmaceutical compositions, antimicrobial-activity compositions, and methods of treating bacterial infections.
On face value, the independent claim (Claim 1) is structured as a Markush-defined core scaffold with multiple independently variable substituents (X, T, A, G, B, D, and an appended E/quaternary-ammonium/cationic ring system), with explicit carve-outs tied to how substituent G and B relate to the cationic N and ring-forming atoms, and a specific exclusion of a different group when “G and B are not present” under certain D settings. Dependent claims then narrow along high-signal axes: discrete values for A, selected G-linker variants, presence/absence and definition of B, defined D patterns, and specific choices for X and functional group substituents on the cationic E component, plus composition and use claims.
What does Claim 1 cover in plain structural terms?
Claim 1 covers:
- A compound defined by a multi-ring / multi-linker formula featuring:
- A variable “X” at one position: N, CH, or C—Cl
- A variable “T” connecting/templating heteroatom or saturation: S, S═O, CH2, or O
- A variable linker “A”: lower alkylene/alkenylene/alkynylene
- An optional “G” substituent, when present limited to specific alkyl chains or alkylene variants optionally substituted by a carbocyclic group
- An optional “B” substituent, when present limited to a 5- or 6-membered heterocycle containing at least one N
- An optional “D” substituent, when present limited to a defined set of carbonyl/heteroatom linkages (including amide and thioether sulfone variants) or “D absent” in Claim 1
- A substituent region “E” containing (i) R1/R2 options (H/halogen/lower alkyl with optional carbamoyl or thioether or phenyl), (ii) R11/R12 options (H/lower alkyl with optional carbamoyl or carboxyl), and (iii) m = 1–5
- A quaternary ammonium group described explicitly as a “optionally substituted, saturated or unsaturated, monocyclic or condensed cyclic quaternary ammonium group” with one or more nitrogens, with substituents limited to halogen, hydroxy, lower alkyl, halo(lower)alkyl, lower alkoxy, and halo(lower)alkoxy, and an explicit bond/“broken line” rule governing whether G bonds to the cationic N
- Equivalents and derivatives explicitly captured:
- “an ester at the carboxyl at the 7-position side chain or at the 4-position”
- “a protected compound at the amino on the ring in the 7-side chain”
- pharmaceutically acceptable salts
- solvate(s)
- A specific negative limitation (important for claim construction):
- When “G and B are not present, and D is —NH—CO— or —S—,” then “a group of the formula … is not a group of the formula …” meaning the claim excludes at least one alternative chemotype within the same Markush frame under those exact combinations.
How does the claim manage quaternary nitrogen connectivity?
Claim 1 includes an explicit definition around the “broken line,” specifying the presence/absence of a bond between a cationic N and a ring-forming atom:
- If G bonds to the cationic N, the broken-line depiction is absent.
- If G does not bond to the cationic N, the broken line represents either:
- a single bond between cationic N and a neighboring atom, or
- a lower alkylene between cationic N and a ring-forming atom other than the neighboring atom.
This matters because it changes whether the claim reads on analogs where the “linker” is a spacer versus a direct bond at the cationic center.
Which structural variables control the breadth of US 9,238,657 Claim 1?
Featured snippet answer: The claim breadth is driven by independent Markush variables for X (N/CH/C-Cl), T (S/S=O/CH2/O), A (lower alkyl/alkenyl/alkynyl), optional G (defined set), optional B (5- or 6-membered N-heterocycles), optional D (defined linker/functional group set), and a quaternary ammonium ring (substituent set restricted by explicit list).
X: N vs CH vs C—Cl
- Dependent claims explicitly lock X values in at least Claim 12 (X = N) and Claim 13 (X = CH or C—Cl), and Claim 15 repeats the combined set.
- Practically, this is a moderate breadth lever: three discrete alternatives, not an open-ended substituent class.
T: S / S═O / CH2 / O
- Claim 14 narrows to T = S.
- The independent claim includes the broader four options, including the oxidized thioether sulfoxide (S═O).
A: linker unsaturation and length class
- Independent Claim 1 allows A = lower alkylene, lower alkenylene, or lower alkynylene.
- Dependent Claim 6 enumerates representative A members including saturated and unsaturated options (e.g., —CH2—, —CH2—CH2—, and alkenyl/alkenyl-alkyl patterns, plus —CH2—CH═CH—).
This yields meaningful claim coverage across different geometry and electron-withdrawing/donating effects while remaining limited to “lower” size.
G: optional, but when present it is tightly defined
In Claim 1, G is “optionally present” and, when present, is limited to:
- —CH2—CH(CH3)—
- —CH2—CH(iPr)—
- lower alkylene optionally substituted with a carbocyclic group
- lower alkenylene
- lower alkynylene
Dependent Claim 7 further narrows G to explicit alkenyl/alkynyl and alkyl variants:
- —CH═CH—
- —CH═CH—CH2—
- —CH2—CH═CH—
- —CH2—CH(CH3)—
- —CH2—CH(iPr)—
- —CH2—CH(Ph)—
So, the independent claim is broad about the type of linker but not broad about the allowed structure class for the linker when the connectivity to the cationic N is involved.
B: optional N-heterocycle
B, when present, is limited to a 5- or 6-membered heterocycle containing at least 1 N atom.
Dependent Claim 8 narrows the “is the formula …” portion for B to specific forms (exact structure not shown in text provided), indicating B can be specific chemotypes rather than a full generic class.
D: optional functional linker set (includes amide, carbonate-like, sulfone, thioether)
Claim 1 defines D as one of:
- —CO—
- —O—CO—
- —CO—O—
- —NR7—
- —NR7—CO—
- —CO—NR7—
- —NR7—CO—NR7—
- —O—
- —S—
- —SO—
- —SO2—NR7—
- —NR7—SO2—
- —CH2—NR7—CO—
- —SO2—
Dependent Claim 9 and Claim 10 split based on whether D is absent and the allowed D sublist:
- Claim 9: D absent or in a subset (including amide-like —NR7—CO— types and thioester-like —CO—NR7— types)
- Claim 10: D optionally present with a different subset
This is a significant breadth driver: D controls functional group identity, polarity, and salt-forming behavior. Yet the selection is enumerated, not open-ended.
E and the quaternary ammonium region: limited substituent lexicon
Claim 1 contains two related variable systems:
- R1/R2 with a narrow list (H, halogen, lower alkyl with optional carbamoyl, lower alkylthio, or phenyl)
- R11/R12 similarly constrained (H, lower alkyl optionally substituted with carbamoyl or carboxyl, plus carboxyl or carbamoyl)
- m is 1–5
Then the quaternary ammonium ring region has a strict substituent list:
- halogen
- hydroxy
- lower alkyl
- halo(lower)alkyl
- lower alkoxy
- halo(lower)alkoxy
This limits how “derivatizable” the cationic system can be while still supporting a wide number of combinations inside that lexicon.
The explicit exclusion (negative limitation)
Claim 1 ends with a structural carve-out:
- When G and B are not present and D is —NH—CO— or —S—, then “a group of the formula … is not a group of the formula ….”
This negative limitation is typically used to avoid overlap with a prior compound family that would otherwise fall inside the broad Markush.
How broad are the dependent claims (2–15) compared with Claim 1?
Featured snippet answer: Dependent claims narrow breadth along high-impact structural axes: they fix specific substructures for A, G, B, D, X, T, and quaternary substituent patterns, reducing the range of covered analogs without changing the overall Markush scaffold.
Claim-by-claim tightening map (high signal from provided text)
- Claim 2: Introduces a specific “formula” variant where n, k, q are integer ranges (n = 0–5, k = 0–5, q = 0–3), and R10 is limited to halogen/hydroxy/lower alkyl/halo(lower)alkyl/lower alkoxy/halo(lower)alkoxy. A and G remain as defined in Claim 1.
- Claim 3: Another fixed structural formula variant with n/k/q/R10 as in Claim 2.
- Claim 4–5: Additional fixed formula instantiations (specific patterns not fully visible in the supplied text).
- Claim 6: Enumerates allowed A values to specific linkers.
- Claim 7: Enumerates allowed G values to a discrete list including phenyl-containing variant (—CH2—CH(Ph)—).
- Claim 8: Fixes B to a specific heterocycle formula.
- Claim 9–10: Restricts D with presence/absence options and enumerated subsets; D defines whether certain carbonyl/heteroatom linkers are included.
- Claim 11: Constrains R8 = H or lower alkyl.
- Claim 12: Constrains X = N.
- Claim 13: Constrains X = CH or C—Cl.
- Claim 14: Constrains T = S.
- Claim 15: Combines multiple constraints simultaneously: X in {N, CH, C—Cl}, T = S, A = lower alkylene, G optionally present but when present is lower alkylene; B absent; n = 0–3; D = —NH—CO— or —CO—NH—; E specified with Me group and R3/R4 = OH and R5/R6 pattern includes H or Cl constraints; F absent.
Net effect: Claim 15 is a compound “species” within the genus of Claim 1 that is still Markush-like in internal parameters but is far more pinned than Claim 1.
Do the claims cover salts, esters, and protected intermediates or only final compounds?
Featured snippet answer: The claim language explicitly includes esters at two defined carboxyl positions, protected compounds at the amino in the 7-side chain, salts, and solvates. That extends coverage beyond the free base/acid form.
- Claim 1: “the compound, or an ester at the carboxyl at the 7-position side chain or at the 4-position, a protected compound at the amino on the ring in the 7-side chain, a pharmaceutically acceptable salt, or a solvate thereof.”
- Dependent claims mirror the same carrier structures (Claims 2–15).
Practical litigation leverage: this can support infringement theories even if an accused product is sold as a salt or ester prodrug form, assuming the structural conditions match the Markush instantiation.
What do the formulation and use claims cover (Claims 16–21)?
Featured snippet answer: Claims 16–21 add composition and method-of-use protection, tied to the claimed compound (and its ester/salt/solvate/protected forms), with antimicrobial activity as a functional limitation and a bacterial-infection treatment method as the therapeutic claim.
Composition and activity
- Claim 16: “A pharmaceutical composition comprising the compound …”
- Claim 17: The pharmaceutical composition “has an antimicrobial activity.”
Functional limitation: “antimicrobial activity” can support enforceability if the composition contains the claimed compound and demonstrates antimicrobial effect, which is often easier than proving structural differences.
Use
- Claim 21: “A method for treating a bacterial infection” by administering the claimed compound (or its esters/protected/salt/solvate) to a subject.
This is a classic method-of-use patent layer that can persist even when formulation changes occur, so long as the accused product delivers the claimed compound (or a covered equivalent) in the body in a way that matches the claim requirements.
How many distinct claim “species” exist in 9,238,657 based on provided text?
Featured snippet answer: At minimum, the patent supports a genus in Claim 1 plus multiple dependent “formula species” in Claims 2–5 and 8, and additional enumerated subfamilies in Claims 6–15. Based on the supplied claim text, there are at least 10 compound-identifying claim layers beyond the independent claim: Claims 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 (with several overlapping constraints).
This means the patent can be asserted in multiple ways against an accused compound depending on which structural features map to the narrower dependent claim sets.
What patent landscape conclusions can be drawn from the claim scope alone?
Featured snippet answer: The claim construction is built to cover a broad set of quaternary ammonium antimicrobials via a disciplined Markush genus, then “ladder down” to multiple narrow anchor species. The presence of connectivity rules around G versus cationic N and the negative limitation in Claim 1 are the main elements likely to control infringement and validity.
IP strength indicators embedded in the claim language
- Quaternary ammonium specificity: The cationic ring is defined not merely as “any quaternary ammonium,” but as an optionally substituted ring system with a restricted substituent lexicon.
- Functional linkage constraints: D and T are enumerated; this reduces the chance the claim reads on chemically distant analogs.
- Explicit bond-geometry rule: “broken line” rule ties linker presence to bonding, tightening claim boundaries.
- Negative limitation: The excluded group under “G and B absent” plus a D condition is a key prosecution artifact and can narrow prior-art overlaps.
IP fragility indicators embedded in the claim language
- Many optional groups: While Markush broadens coverage, it also creates more ways to argue non-infringement if a competitor’s structure swaps a linker class outside the enumerated lists.
- Dependent claims are formula-pinned: Competitors that design around the most constrained subfamilies may still avoid dependent claims even if they practice only non-covered variants relative to Claim 1’s exact substituent definitions.
What generic entry risks exist for compounds covered by this patent?
Featured snippet answer: For antimicrobial small molecules covered as new chemical entities, the main “generic entry” risk is not a typical ANDA scenario unless there is an FDA-approved reference product containing a covered compound and the generics seek to market the same active ingredient. In that setting, Paragraph IV challenges would target Orange Book-listed patents that cover the active ingredient, salts/esters, or methods.
However, within the patent itself, the strongest generic-risk vectors are:
- Marketing a covered salt or ester form rather than the free base/acid
- Marketing a prodrug/protected variant that falls within the “protected compound at the amino” coverage (often a battleground)
- Designing around the quaternary cation connectivity rules and the D/T/G/B enumerated lists
Given the claim text provided, the patent is structured to anticipate design-around attempts by defining a connectivity relationship and by enumerating several families of allowable linkers.
Key Takeaways
- US 9,238,657 Claim 1 is a Markush-defined genus for quaternary ammonium-containing antimicrobial compounds, with discrete enumerated options for X, T, A, and D, plus optional G and B that are constrained when present.
- The quaternary ammonium ring substituents are limited to a specific set (halogen, hydroxy, lower alkyl, halo(lower)alkyl, lower alkoxy, halo(lower)alkoxy), tightening chemical scope.
- Connectivity rules between G and the cationic N (broken-line depiction rule) and a negative limitation (specific excluded group under “G and B absent” plus D conditions) are the main claim-boundary controls.
- Dependent claims 2–15 function as “claim ladder” species coverage, pinning discrete substructures for A, G, B, D, X, T, and cationic substituent patterns.
- Claims 16–17 provide composition protection with antimicrobial activity, and Claim 21 provides a method-of-use for treating bacterial infections using the claimed compound and covered derivatives (esters/salts/solvates/protected forms).
FAQs
1) Does US 9,238,657 claim prodrugs and protected intermediates or only marketed active ingredient forms?
Yes. Claim 1 expressly includes an ester at specified carboxyl positions and a “protected compound at the amino on the ring in the 7-side chain,” plus salts and solvates.
2) What parts of the structure are the easiest to design around?
Likely the enumerated linker/functional group options for T, D, and the optional presence and exact definition of G and B, since the claim restricts these to listed subclasses rather than open-ended chemistry.
3) Is the quaternary ammonium ring broadly defined or tightly constrained?
Tightly constrained by a defined quaternary ammonium ring description and a restricted substituent lexicon limited to halogen/hydroxy/lower alkyl/halo(lower)alkyl/lower alkoxy/halo(lower)alkoxy.
4) Do the claims require a specific therapeutic indication beyond “bacterial infection”?
Claim 21 requires administering to treat a bacterial infection; it does not add organism-specific or site-specific limitations in the provided text.
5) Are composition claims limited to specific dosage forms?
The provided claim text does not specify dosage form; Claim 16 is a composition “comprising” the compound, while Claim 17 adds antimicrobial activity.
References (APA)
- US Patent 9,238,657.
